[575] In the 2017 publication, Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline, the American Society of Clinical Oncology (ASCO) recommended clinician training in communication skills and discussion of goals of care and prognosis, treatment selection, end-of-life care, and facilitating family involvement in care
This analysis to reduce selection bias was performed using propensity score (PS) matching method and adjusting with the confounding factors

200mg/10mL (20mg/mL)(PF) 10mL fill in 12mL Single Dose Syr Compounded 08132019@5 10/12/2019 Tropicamide 1%/Cyclopentolate 1% /Phenylephrine 2.5%/Ketorolac 0.5% Oph Sol 0.5mL Syr, Compounded 06212019@39 9/19/2019 Tropicamide 1%/Cyclopentolate 1% /Phenylephrine 2.5%/Ketorolac 0.5% Oph Sol 0.5mL Syr, Compounded 06272019@12 9/25/2019 Tropicamide 1%/Cyclopentolate 1% /Phenylephrine 2.5%/Ketorolac 0.5% Oph Sol 0.5mL Syr, Compounded 07272019@14 10/25/2019 Tropicamide 1%/Cyclopentolate 1%/Phenylephrine 10%/Ketorolac 0.5% Oph Sol 5mL Droptainer, Compounded 07202019@17 10/18/2019 Tropicamide 1%/Cyclopentolate 1%/Phenylephrine 2.5% (Contains Sulf) Oph Sol 5mL Droptainer, Compound 08082019@13 10/7/2019 Tropicamide 1%/Cyclopentolate 1%/Phenylephrine 2.5%/Ketorolac 0.5% Oph Sol 3mL Droptainer Compounded 06142019@24 9/12/2019 Tropicamide 1%/Cyclopentolate HCl 1%/Phenylephrine HCl 2.5% Oph Sol
For example, a 1,000 mcg dose might be in 1 mL of solution, but this can vary with different formulations
By skipping the digestive tract, the IM method ensures that a high percentage of the glutathione remains intact